Switching from natalizumab to fingolimod: risk of disease reactivation during the washout period is due to the previous activity of the disease. Follow-up of the ENIGM survey

M. Cohen,E. Maillart,C. Papeix,S. Vukusic,D. Brassat,J. De Seze, A. Tourbah,S. Wiertlewski,D. Laplaud,W. Camu,S. Courtois, F. Derouiche, L. Chambaud,C. Boulay, B. Brochet,M. Debouverie,O. Casez,O. Heinzlef, J. Ouallet, B. Stankoff,G. Castelnovo,E. Le Page,G. Defer,N. Derache, O. Anne,E. Berger,J. Camdessanche,A. Kopf,M. Fleury,I. Malikova,J. Pelletier,A. Al Khedr,C. Zaenker,G. Edan,T. Moreau, A. Fromont, A. Rico, F. Blanc,N. Collongues, P. Barth, P. Louiset,S. Pittion,P. Clavelou, F. Thaite,P. Vermersch, H. Sephir, A. Creange,O. Gout, A. Guennoc,M. Coustans, G. Thaurin, F. Lallement, F. Rouhart,E. Thouvenot, P. Labauge, P. Seeldrayers,C. Lebrun

MULTIPLE SCLEROSIS JOURNAL(2013)

Cited 0|Views5
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined